| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
The intermediate itself has no direct biological target. Monomethyl auristatin E (MMAE), the final API for which this intermediate is used, is a tubulin polymerization inhibitor that binds to the vinca domain on tubulin, preventing microtubule assembly and leading to G2/M phase cell cycle arrest and apoptosis.
|
|---|---|
| ln Vitro |
Monomethyl auristatin E intermediate-14 has no direct in vitro activity. However, MMAE exhibits potent cytotoxic activity against various cancer cell lines, including NCI-H460 (IC50 ≈ 0.1 nM), HCT-116 (IC50 ≈ 0.3 nM), and other rapidly dividing cells.
|
| ln Vivo |
The intermediate itself has no direct in vivo activity. MMAE, when conjugated as an ADC payload, demonstrates significant antitumor efficacy in xenograft models at doses as low as 0.1-1 mg/kg (IV), with complete tumor regressions observed in some models.
|
| Enzyme Assay |
Monomethyl auristatin E intermediate-14 is a chemical intermediate and is not used in enzyme or receptor binding assays. For quality control, HPLC (≥98% purity) and LC-MS are employed to verify the identity, purity, and structure of the compound according to specifications.
|
| Cell Assay |
Cell-based assays are not applicable to this synthetic intermediate. For MMAE, typical protocols involve seeding cancer cells (5000-10000 cells/well) in 96-well plates overnight, treating with serial dilutions of MMAE (0.001 nM to 100 nM) for 48-72 hours, and measuring viability via MTT or CellTiter-Glo.
|
| Animal Protocol |
Taltobulin intermediate-2 is a synthetic intermediate used in the preparation of Taltobulin , a potent microtubule/tubulin inhibitor. Taltobulin is commonly employed as a cytotoxic payload in antibody-drug conjugate (ADC) development, where it disrupts tubulin polymerization, leading to mitotic arrest and apoptosis in cancer cells. As an intermediate, this compound itself does not possess direct biological activity; its value lies in its defined role in validated synthetic routes to the final active pharmaceutical ingredient. It is supplied as a research-grade chemical for laboratory-scale synthesis.
|
| ADME/Pharmacokinetics |
Taltobulin intermediate-2 itself has no direct biological target. However, its downstream product Taltobulin targets tubulin (microtubules), disrupting polymerization and inducing mitotic arrest.
|
| Toxicity/Toxicokinetics |
Taltobulin intermediate-2 as a synthetic building block has no direct in vitro activity. However, the final API Taltobulin exhibits potent antimicrotubule activity with IC50 values in the low nanomolar range against various cancer cell lines and circumvents P-glycoprotein-mediated resistance.
|
| References |
[1]. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87.
|
| Additional Infomation |
Taltobulin intermediate-2 has no direct in vivo activity. Taltobulin, the compound for whose synthesis this intermediate is used, demonstrates potent antitumor efficacy in xenograft models and is effective against multidrug-resistant tumors.
|
| Molecular Formula |
C13H19NO2
|
|---|---|
| Molecular Weight |
221.30
|
| Exact Mass |
221.142
|
| CAS # |
1932791-56-4
|
| PubChem CID |
56845762
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
16
|
| Complexity |
212
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC[C@H](C)[C@H](C(=O)O)NCC1=CC=CC=C1
|
| InChi Key |
GPAVORZIWQTJJQ-CMPLNLGQSA-N
|
| InChi Code |
InChI=1S/C13H19NO2/c1-3-10(2)12(13(15)16)14-9-11-7-5-4-6-8-11/h4-8,10,12,14H,3,9H2,1-2H3,(H,15,16)/t10-,12+/m0/s1
|
| Chemical Name |
(2R,3S)-2-(benzylamino)-3-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5188 mL | 22.5938 mL | 45.1875 mL | |
| 5 mM | 0.9038 mL | 4.5188 mL | 9.0375 mL | |
| 10 mM | 0.4519 mL | 2.2594 mL | 4.5188 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
